EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

From Oxyntomodulin to Retatrutide: A Translational Review of Metabolic Polyagonism

Héctor Iván Saldívar-Cerón iD, Daniela Maldonado-Trejo, Quetzal Chavez-Castañeda iD, Ana Lorena Mercado-Guzmán, Angela de Jesús León-Barrita, Isela Alejandra López-García, Alejandra Hernández-Solís, Andrés Moranchel Ramírez-Mendoza, Daniela Alejandra Terrazas-Delgado, Ari Evelyn Castañeda-Ramírez, Efrén Quiñones-Lara iD, Brenda Ofelia Jay-Jímenez und 2 weitere

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27219654 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Héctor Iván Saldívar-Cerón und 13 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Remisión de Diabetes Mellitus (URDM), Carrera de Médico Cirujano, Facultad de Estudios Superiores-Iztacala, Universidad Nacional Autónoma d…. Hauptthemen laut MEDLINE: Oxyntomodulin, Receptors, Glucagon. Die Arbeit nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oxyntomodulin (OXM), an endogenous proglucagon-derived peptide with dual glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) agonism, provides a physiological precedent for contemporary multi-receptor pharmacology. Recognition that GCGR signaling regulates not only hepatic glucose production but also amino acid turnover, lipid metabolism, substrate oxidation, and energy expenditure prompted the development of engineered GLP-1R/GCGR co-agonists, including cotadutide, mazdutide, survodutide, and pemvidutide. Retatrutide extends this strategy by integrating GIPR, GLP-1R, and GCGR agonism within a single long-acting peptide and has produced substantial improvements in body weight, glycemic control, and cardiometabolic parameters in phase 2 and phase 3 trials. This review examines the evolutionary and structural relationships of the proglucagon–Class B1 GPCR system, OXM biosynthesis and receptor pharmacology, the mechanistic rationale for therapeutic GCGR agonism, and the molecular and clinical development of dual and triple agonists. We further address receptor balance, the GIPR agonism–antagonism paradox, receptor-specific causal attribution, and the unresolved limitations of translating molecular pharmacology into durable clinical benefit. Finally, we propose an Activity–Exposure–Context framework for interpreting polyagonist pharmacology and discuss prospective enteroinsular phenotyping using standardized mixed-meal testing as a testable strategy to investigate interindividual variability in therapeutic response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OxyntomodulinReceptors, GlucagonHumansAnimalsGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-1 ReceptorFatty AcidsPeptides

Stichwörter der Autor:innen

Class B1 GPCRGIP receptorGLP-1 receptorglucagon receptormixed-meal tolerance testoxyntomodulinpolyagonismreceptor pharmacologyretatrutidetreatment-response heterogeneity

Substanzen

OxyntomodulinReceptors, GlucagonGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-1 ReceptorretatrutideFatty AcidsPeptides

Autor:innen und Institutionen

  • Unidad de Remisión de Diabetes Mellitus (URDM), Carrera de Médico Cirujano, Facultad de Estudios Superiores-Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Estado de Mexico, Mexico.
  • Departamento de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Ciudad de Mexico 07360, Mexico.
  • Centro Internacional de Simulación y Entrenamiento en Soporte Vital Iztacala (CISESVI), Facultad de Estudios Superiores-Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Estado de Mexico, Mexico.
  • Laboratorio de Genética y Oncología Molecular, Carrera de Médico Cirujano, Facultad de Estudios Superiores-Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Estado de Mexico, Mexico.
  • Unidad de Biomedicina (UBIMED), Carrera de Médico Cirujano, Facultad de Estudios Superiores-Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla 54090, Estado de Mexico, Mexico.

ORCID-Profile: Héctor Iván Saldívar-Cerón, Quetzal Chavez-Castañeda, Efrén Quiñones-Lara, Glustein Pozo-Molina, Sonia León-Cabrera

Zitieren

APA

Saldívar-Cerón, H. I., Maldonado-Trejo, D., Chavez-Castañeda, Q., Mercado-Guzmán, A. L., León-Barrita, A. J., López-García, I. A., Hernández-Solís, A., Ramírez-Mendoza, A. M., Terrazas-Delgado, D. A., Castañeda-Ramírez, A. E., Quiñones-Lara, E., Jay-Jímenez, B. O., Pozo-Molina, G., & León-Cabrera, S. (2026). From Oxyntomodulin to Retatrutide: A Translational Review of Metabolic Polyagonism. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27219654

Vancouver

Saldívar-Cerón HI, Maldonado-Trejo D, Chavez-Castañeda Q, Mercado-Guzmán AL, León-Barrita AJ, López-García IA, et al. From Oxyntomodulin to Retatrutide: A Translational Review of Metabolic Polyagonism. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27219654

BibTeX
@article{SaldvarCern2026,
  author = {Saldívar-Cerón, Héctor Iván and Maldonado-Trejo, Daniela and Chavez-Castañeda, Quetzal and Mercado-Guzmán, Ana Lorena and León-Barrita, Angela de Jesús and López-García, Isela Alejandra and Hernández-Solís, Alejandra and Ramírez-Mendoza, Andrés Moranchel and Terrazas-Delgado, Daniela Alejandra and Castañeda-Ramírez, Ari Evelyn and Quiñones-Lara, Efrén and Jay-Jímenez, Brenda Ofelia and Pozo-Molina, Glustein and León-Cabrera, Sonia},
  title = {From Oxyntomodulin to Retatrutide: A Translational Review of Metabolic Polyagonism},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27219654}
}
Kostenlos starten →